marked.bio

ALK TKI (2nd generation) · small molecule

iruplinalkib

3 active trials across 2 of our biomarkers, targeting ALK/ROS1. Not approved for any biomarker on marked.bio yet.

Also known as WX-0593.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 3 8 Phase 2
ROS1 fusion 1 4 Phase 2

Trials

3 of 9 trials shown

  1. Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

    Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2024Primary completion 2025-06 NCT06282536

    iruplinalkib

    …f NSCLC by needle biopsy, and evaluated by researchers as stage III-IVA, and diagnosed as ALK positive through genetic testing.

    ALK fusionStatus may be outdated, last updated 2024-02-28Potentially Resectable ALK Positive Non-Small Cell Lung Cancer

  2. Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

    Recruiting Phase 2 Pingping Song Started 2023Primary completion 2027-03 NCT05765877

    iruplinalkib

    ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on…

    ALK fusionROS1 fusionNon-Small Cell Lung Cancer(NSCLC)

  3. Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial

    Not yet recruiting No phase Shanghai Pulmonary Hospital, Shanghai Started 2026Primary completion 2029-07 NCT07870733

    bevacizumabiruplinalkib

    Stage II-III NSCLC per investigator, and ALK-positive.

    ALK fusionALK, NSCLC, Neoadjuvant Therapy